Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and gemcitabine in elderly metastatic pancreatic cancer
NCT02391662Phase 2Completed
- Sponsor
- Hospital Universitario Cruces - Servicio de Oncología Médica
- Start
- Jun 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Hospital Universitario Cruces - Servicio de Oncología Médica. Primary endpoint: 3-months deterioration free rate. Started Jun 2015; status: completed.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02391662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391662.